濮阳东方男科医院可靠吗濮阳东方医院治阳痿价格收费合理,濮阳东方妇科专家怎么样,濮阳东方妇科非常的专业,濮阳东方男科医院收费查询,濮阳东方医院值得信赖,濮阳东方医院看阳痿价格低,濮阳市东方医院评价高专业

LOS ANGELES, May 6 (Xinhua) -- Limiting prolonged bottle use in children may be an effective way to help prevent obesity, a new study suggests.For the study, researchers from the Center for Obesity Research and Education at Temple University (CORETU) and the Ohio State University College of Public Health analyzed data from 6,750 children to estimate the association between bottle use at 24 months of age and the risk of obesity at 5.5 years of age, according to the Science Daily on Friday.Of the children studied, 22 percent were prolonged bottle users, meaning that at two years of age they used a bottle as their primary drink container and/or were put to bed with a calorie- containing bottle.The findings showed that nearly 23 percent of the prolonged bottle users were obese by the time they were 5.5 years old."Children who were still using a bottle at 24 months were approximately 30 percent more likely to be obese at 5.5 years, even after accounting for other factors such as the mother's weight, the child's birth weight, and feeding practices during infancy," said Dr. Robert Whitaker at CORETU, lead author of the study.Drinking from a bottle beyond infancy may contribute to obesity by encouraging the child to consume too many calories, the researchers noted."A 24-month-old girl of average weight and height who is put to bed with an eight-ounce bottle of whole milk would receive approximately 12 percent of her daily caloric needs from that bottle," explained co-author Rachel Gooze.Gooze noted that weaning children from the bottle by the time they are one year of age is unlikely to cause harm and may prevent obesity. The authors suggested that pediatricians and other health professionals work with parents to find acceptable solutions for stopping bottle use at the child's first birthday.The findings adds new evidence to the theory that obesity prevention should begin before children enter school, the researchers said.

WASHINGTON, April 13 (Xinhua) -- The U.S. Food and Drug Administration (FDA) announced on Wednesday that it has approved the cPAX Aneurysm Treatment System for surgery on brain aneurysms that are difficult to manage because of their size and shape.An aneurysm is a bulge in the wall of a blood vessel, which can rupture as it increases in size, causing hemorrhage or death. Brain aneurysms often produce no symptoms until they grow and press on nerves in the brain, or until they begin to leak blood or rupture.Aneurysms can be repaired in two ways: surgeons can close the base of the aneurysm with a surgical clip, or use a technique commonly known as coiling, in which surgeons use a catheter to thread metallic coils through a blood vessel in the groin and into the blood vessel in the brain that contains the aneurysm. Surgeons then fill the aneurysm with the detachable coils, which block it from circulation and cause blood to clot, effectively destroying the aneurysm.Aneurysms larger than 10 millimeters are difficult to treat with clipping or coiling. The cPAX device system is indicated for use in those brain aneurysms."Like coiling, the cPAX Aneurysm Treatment System is a form of endovascular repair," said Christy Foreman, director of the Office of Device Evaluation in the FDA's Center for Devices and Radiological Health. "But instead of tiny metallic coils, it uses a special polymer material to fill the space within the aneurysm."According to the FDA, the cPAX device system is indicated for use in adults aged 22 and older and should not be used in patients with an active infection or in those in whom anticoagulation and antiplatelet therapy is contraindicated.

NANJING, April 23 (Xinhua) -- At a time when almost every commodity in China is getting more expensive, the dwindling cost of medicine is a rarity.Zhang Jinkui, a hypertension patient, buys medicines from the community health center of his neighborhood in Changzhou, a city in east China's coastal Jiangsu Province.His prescription list includes Aspirin Enteric-coated tablets, down to 1.4 yuan from 4.7 yuan (0.7 U.S. dollars) per unit, and Fosinopril Sodium Tablets, down to 41.39 yuan from 51.6 yuan per unit.Both drugs are found on the essential drug list unveiled in 2009. The list names the 307 most common western and traditional Chinese medicines, which are heavily subsidized so hospitals can sell them at cost price.A consumer buys medicines with the help of a retailer at a pharmacy in Lianyungang, east China's Jiangsu Province, March 28, 2011.All essential medicines are listed by their generic names, and drug producers compete to supply essential medicines through public procurement.Due to a long history of low government funding for state-run hospitals, which often covers only 10 percent of the hospitals' operating costs, doctors have generated income for hospitals by aggressively prescribing expensive, and sometimes unnecessary, medicines and treatments.The essential medicine system and the reform of publicly funded hospitals, two pillars of China's health reform, are designed to address high medical costs and low accessibility of medical services.In April 2009, China kicked off health reforms aimed at correcting these long-standing problems facing China's health system and easing public grievances.Two years later, the essential medicine system has reduced drug prices, but still fails to please hospitals, patients and drug producers.The system requires government-funded grassroots health clinics, including urban community health centers and rural clinics, to prescribe only essential medicines and to sell these medicines at cost price, rather than with the previous 15 percent mark-up.Such policies have brought hard times to grassroots health clinics, especially in cash-strapped areas.Song Wenzhi, a public health professor at Peking University, said "Grassroots health clinics, without the expertise to perform operations and other treatments, rely heavily on selling drug," adding that these hospitals have found themselves scraping by due to the zero percent mark-up policy.Wang Zhiying, Vice Director of the People's Hospital of Anxiang County in the city of Changde, Hunan Province, said four grassroots hospitals in Changde tested the essential medicine system as pilot projects, but the zero percent mark-up policy took away 60 to 70 percent of the hospitals' revenue.Wang was quoted by "Health News," a newspaper run by China's Ministry of Health, as saying that, due to financial difficulties, the county government had not yet channeled the 8 million yuan (1.2 million U.S.dollars) in support funds into the hospitals' accounts, resulting in the resignations of many doctors.The essential medicine system covers 60 percent of government-funded grassroots hospitals and drug prices have fallen by an average of 30 percent, said Sun Zhigang, Director of the Health Reform Office under the State Council, or China's Cabinet.According to the health reform plan for 2011, the essential medicine system will cover all government-sponsored health institutions at the grassroots level by the end of the year and drugs will be sold there at a zero percent mark-up.Song Wenzhi said the key will be the commitment of local governments to health reform and their financial input. This way, essential medicines can benefit the public without bankrupting grassroots health institutions."That would be a great sum of money." said Song, citing his own studies. "There are roughly 5,000 government-funded hospitals in China. One third of them make profits, one third barely break even, and still one third rely heavily on government subsidies."To maintain the poorest hospitals, central and local level governments would need to invest 15 billion yuan (2.3 billion U.S. dollars) each year, according to Song's estimate.

BEIJING, Jan. 26 (Xinhua) -- China's top leaders Wednesday evening attended a gala held at the Great Hall of the People to celebrate the coming Chinese lunar new year, which falls on Feb. 3, with armymen and the common people.Chinese President Hu Jintao and other members of the Standing Committee of the Political Bureau of the Communist Party of China (CPC) Central Committee Wu Bangguo, Wen Jiabao, Jia Qinglin, Li Changchun, Xi Jinping, Li Keqiang, He Guoqiang and Zhou Yongkang, watched the artistic performance and extended their festival greetings to the audience.Chinese top leaders Hu Jintao, Wu Bangguo, Wen Jiabao, Jia Qinglin, Li Changchun, Xi Jinping, Li Keqiang, He Guoqiang and Zhou Yongkang pose with performers for a group photo after an evening party welcoming the upcoming Chinese traditional Spring Festival in Beijing, capital of China, Jan. 26, 2011. Military and civilian artists presented various programs at the gala ranging from Peking Opera, chorus to acrobatic shows, which were welcomed and hailed by the audience.

BEIJING, March 22 (Xinhua) -- China's State Food and Drug Administration (SFDA) has ordered a "serious investigation" into two kinds of bath products that reportedly gave children skin diseases.The order came after recent reports accused the body wash and lotion used by bathhouse chain Tian Po Po Xi Jiu Tang, or, literally, "Grandma Tian's Bathhouse," in southwest China's Sichuan Province of having "caused severe body damages," according to a SFDA statement released Tuesday.The bathhouse chain, with a history of some 70 years, was first established in Sichuan's capital Chengdu and was listed as a part of the city's Intangible Cultural Heritage in 2009.The licensed bathhouse claimed to use bath products developed by its own Chinese herbal medicine recipes that protected children from various skin ailments and other diseases, such as eczema, colds, and constipation.However, an unknown number of children suffered pustular psoriasis, a chronic skin irritation characterize by raised bumps, after washing at the bathhouse chain and using the two products, according to reports.Sichuan's provincial food and drug administration bureau previously deemed the two products to be "fake drugs" based on an initial investigation by the local police and food and drug authorities, the statement said.The SFDA urged local food and drug supervision departments across the country to monitor and check the two products sold by the bathhouse chain within their regions, and vowed to punish any violations of laws and regulations.